Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drug shows promise in Year-Long trial

NCT ID NCT01387737

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medication, TA-7284, in 1,299 adults with type 2 diabetes over 52 weeks. The goal was to see if the drug is safe and helps control blood sugar when used alone or with other diabetes medicines. Results focused on side effects, blood sugar levels, and weight changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,299 people

The number who actually took part.

Start date

May 2011

Finished

Dec 2012

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women age ≥20 years old * Diagnosed with Type 2 diabetes mellitus at least 3 months before screening * HbA1c of ≥7.0% and ≤10.0% (monotherapy group) * HbA1c of ≥7.0% and ≤10.5% (combination therapy group) Exclusion Criteria: * Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus * Past or current history of severe diabetic complications * Fasting plasma glucose \> 270 mg/dL before treatment start * History of hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients requiring insulin therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research site

    Chugoku, Japan

  • Research site

    Hokkaido, Japan

  • Research site

    Kanto, Japan

  • Research site

    Kinki, Japan

  • Research site

    Kyushu, Japan

  • Research site

    Shikoku, Japan

  • Research site

    Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.